![Avicanna Inc](/common/images/company/T_AVCN.png)
This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna...
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual...
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing...
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of...
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound...
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development...
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development...
$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.155 | -31.3131313131 | 0.495 | 0.5 | 0.33 | 86619 | 0.38282078 | CS |
4 | -0.02 | -5.55555555556 | 0.36 | 0.55 | 0.33 | 158676 | 0.41570667 | CS |
12 | -0.02 | -5.55555555556 | 0.36 | 0.55 | 0.2 | 165318 | 0.32265214 | CS |
26 | 0.025 | 7.93650793651 | 0.315 | 0.6 | 0.2 | 133704 | 0.37241476 | CS |
52 | 0.035 | 11.4754098361 | 0.305 | 0.6 | 0.2 | 153153 | 0.34352078 | CS |
156 | -0.67 | -66.3366336634 | 1.01 | 1.01 | 0.16 | 85725 | 0.36946827 | CS |
260 | -5.86 | -94.5161290323 | 6.2 | 6.2 | 0.16 | 76201 | 0.87494731 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.